BurstIQ is the First and Only Blockchain Data Platform to Receive SOC 2 Type 2 Certification

FlowMetric Life Sciences, Inc., a global provider of specialty flow cytometry services and personalized medicine testing products, announced this week that the company has entered into partnership with BurstIQ, a leader in the healthcare blockchain data sector.

FlowMetric’s enterprise-level deployment of the BurstIQ blockchain platform marks a first for the life sciences, biotech and pharmaceutical industry. Initial applications will focus on FlowMetric’s direct-to-consumer line of health and wellness testing products. Coupling this service with the BurstIQ blockchain platform will provide consumers with unprecedented data security and the ability to govern how their personal information is shared, utilized and monetized. FlowMetric’s full suite of personalized medicine products, which will initially include chromosomal age tests, cellular toxicity analysis, oxidative stress and inflammation monitoring, will utilize BurstIQ’s digital token-based monetization platform (Token: BIQ) and will be offered through BurstIQ’s healthcare marketplace.

Future phases of the partnership will bring BurstIQ’s proprietary blockchain platform and its advanced intelligence layer to FlowMetric’s Fortune 500 pharmaceutical customers, enabling secure and auditable chain of custody tracking for clinical sample analysis and secure data exchange between FlowMetric and its enterprise customers.

“The future of data is in blockchain,” says Ren Capocasale, CEO of FlowMetric. “The BurstIQ platform will allow us to offer a level of service to both our enterprise and individual customers that is truly best in class. In addition, it opens new distribution and partnership channels that will accelerate our growth.”

Christopher P. Molineaux, President and CEO of Life Sciences PA notes, “It’s notable that once again, entrepreneurial, Pennsylvania-based companies like FlowMetric lead the way by adopting revolutionary technologies such as blockchain to optimize their flow cytometry services and ultimately enhance patient care.”

“The expansion of promise of blockchain technologies has now reached personalized medicine, where security and control of information are paramount,” notes Anthony P Green, PhD., Vice President, Technology Commercialization Group at the Ben Franklin Technology Partners of Southeastern PA. “This novel partnership between FlowMetric and BurstIQ can address and mitigate these very real concerns and has the potential to impact an entire industry.”

Frank Ricotta, CEO of BurstIQ, commented; “Our partnership with FlowMetric sets the foundation for an entirely new economy in which the value of health data can be fully realized. Individuals who have a FlowMetric personalized medicine test completed will be able to access and control their test results, combine it with other health data, and gain real value from that data through marketplaces of products, services and research opportunities tailored just for them. FlowMetric’s suite of personalized medicine products is an essential component of this new economy.”

About FlowMetric™

The FlowMetric Life Sciences™ family of companies is driven to provide Flow Cytometry Solutions in Precision Medicine. FlowMetric and its European affiliate, FlowMetric Europe are leading Contract Research Organizations in the delivery of high-complexity, polychromatic flow cytometry and cell sorting services to the Global life sciences industry, with an uncompromising commitment to quality and innovation. FlowMetric Diagnostics is translating this expertise into advanced wellness solutions for a better life.

For more information visit: www.FlowMetric.com | Facebook | Twitter | LinkedIn

About BurstIQ

BurstIQ™ is an industry-leading blockchain enablement company, offering enterprise-level blockchain solutions for the health and healthcare industry. The company offers a HIPAA- and GDPR- compliant platform that seamlessly leverages blockchain, advanced security, Big Data capabilities and machine intelligence to enable a global health data network through which healthcare businesses and individuals can access, control, monetize and gain insights from their health data. The company provides platform-as-a-service (PaaS) solutions to healthcare institutions, insurers life sciences/pharma companies and government agencies at the state, national and international level.

For more information visit: www.burstiq.com| Facebook| Twitter| LinkedIn| YouTube

Contacts

FlowMetric Life Sciences:
Rachel Bunting, MS, MBA
VP of Global Sales & Marketing
[email protected]

PR & Media Contact:

Matthew Bird
CEO @1800pr
1-800-PublicRelations
O: 646.401.4499
E: [email protected]

BurstIQ Business Inquiries:

Amber Hartley
Chief Corporate Development Officer
E: [email protected]
W: www.burstIQ.com